Clinical Trial

Efficacy and Safety Study of Romiplostim N01 for Cancer Treatment-induced Thrombocytopenia (CTIT) in the Treatment of Leukemia

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Evaluation of the Efficacy and Safety of Romiplostim N01 for the Treatment of Cancer Treatment-Induced Thrombocytopenia (CTIT) in Patients with Leukemia
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-03-21; most recent amendment 2026-07-09.
Status change: Not Yet Recruiting → Recruiting 2026-07-09
Trial Details
NCT Number NCT06898983
Lead Sponsor Anhui Provincial Hospital
Conditions Cancer Treatment-induced Thrombocytopenia (CTIT)
Enrollment 97 participants
Start Date 2025-07-14
Primary Completion 2026-06-30 (estimated)
Study Completion 2027-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-10